Integrative analysis reveals different feature of intrahepatic cholangiocarcinoma subtypes
Liver International · 2024
DOI: 10.1111/liv.16015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Zhuomiaoyu Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, UMHS-PUHSC Joint Institute for Translational and Clinical Research, Capital's Funds for Health Improvement and Research.
Abstract (Originalsprache)
Background & Aims Intrahepatic cholangiocarcinoma (iCCA) has two main histological subtypes: large and small duct‐type iCCA, which are characterized by different clinicopathological features. This study was conducted with the purpose of expanding our understanding of their differences in molecular features and immune microenvironment.
Methods
We selected 132 patients who underwent radical surgery at our department between 2015 and 2021 for clinical and survival analyses. Whole‐exome sequencing was performed to analyse mutational landscapes. Bulk RNA sequencing and single‐cell RNA sequencing data were used for pathway enrichment and immune infiltration analyses based on differentially expressed genes. The function of PPP1R1B was analysed both in vitro and in vivo and the gene mechanism was further investigated.
Results
We found that large duct‐type iCCA had worse overall survival and recurrence‐free survival rates than small duct‐type iCCA. Mutations in ARID1A , DOT1L and ELF3 usually occur in large duct‐type iCCA, whereas mutations in IDH1 and BAP1 occur in small duct‐type iCCA. Among the differentially expressed genes, we found that PPP1R1B was highly expressed in large duct‐type iCCA tumour tissues. Expression of PPP1R1B promoted cell proliferation, migration and invasion and indicated a worse prognosis. A combination of USF2 with the promoter of PPP1R1B can enhance gene expression in iCCA, which may further affect the expression of genes such as AHNAK , C4BPA and activating the PI3K/AKT pathway.
Conclusions
Our findings extend our understanding of large and small duct‐type iCCA. In addition, PPP1R1B may serve as a potential marker and therapeutic target for large duct‐type iCCA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China.
- Beijing Key Laboratory of HCC and Liver Cirrhosis, Peking University People's Hospital, Beijing, China.
- Peking University Center of Liver Cancer Diagnosis and Treatment, Peking University People's Hospital, Beijing, China.
- Peking University Institute of Organ Transplantation, Peking University People's Hospital, Beijing, China.
ORCID-Profile: Zhuomiaoyu Chen, Jie Gao, Zuyin Li, Delin Ma, Yang Wang, Qian Cheng, Jiye Zhu, Zhao Li
Förderung
- National Natural Science Foundation of China
- UMHS-PUHSC Joint Institute for Translational and Clinical Research
- Capital's Funds for Health Improvement and Research
Zitieren
APA
Chen, Z., Gao, J., Li, Z., Ma, D., Wang, Y., Cheng, Q., Zhu, J., & Li, Z. (2024). Integrative analysis reveals different feature of intrahepatic cholangiocarcinoma subtypes. Liver International. https://doi.org/10.1111/liv.16015
Vancouver
Chen Z, Gao J, Li Z, Ma D, Wang Y, Cheng Q, et al. Integrative analysis reveals different feature of intrahepatic cholangiocarcinoma subtypes. Liver International. 2024. doi:10.1111/liv.16015
BibTeX
@article{Chen2024,
author = {Chen, Zhuomiaoyu and Gao, Jie and Li, Zuyin and Ma, Delin and Wang, Yang and Cheng, Qian and Zhu, Jiye and Li, Zhao},
title = {Integrative analysis reveals different feature of intrahepatic cholangiocarcinoma subtypes},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.16015}
}
EUVIMED